Cat:GMP-IVD-P048-Tg001
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-IVD-P048-Tg001 Categories , Tag

Product Details

Genemedi produces core diagnostic ingredients for test of Infectious disease (COVID-19) and related syndrome. GeneMedi offers paired diagnostics grade Nucleocapsid protein (Nucleocapsid) antibodies (monoclonal antibody, mab) and antigens for Infectious disease (COVID-19) rapid test kit of Nucleocapsid protein (Nucleocapsid) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Infectious disease (COVID-19 ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.The nucleocapsids of enveloped?RNA viruses?are fairly simple structures that contain only one major structural protein, often referred to as the nucleocapsid protein or core protein. This protein is usually quite basic or has a basic domain. It binds to the viral RNA and encapsidates it to form the nucleocapsid. For most RNA viruses, nucleocapsids can be recognized as distinct structures within the infected cell and can be isolated from virions by treatment with detergents that dissolve the envelope. The nucleocapsids of?alphaviruses, and probably flaviviruses and?arteriviruses?as well, are regular icosahedral structures, and there are no other proteins within the nucleocapsid other than the nucleocapsid protein. In contrast, the nucleocapsids of all minus-strand viruses are helical and contain, in addition to the major nucleocapsid protein, two or more minor proteins that possess?enzymatic activity. As described, the nucleocapsids of minus-strand RNA viruses remain intact within the cell during the entire infection cycle and serve as machines that make viral RNA. The?coronaviruses?also have helical nucleocapsids, but being plus-strand RNA viruses they do not need to carry enzymes in the virion to initiate infection. The helical nucleocapsids?of (-) RNA viruses appear disordered within the envelope of all viruses except the?rhabdoviruses, in which they are coiled in a regular fashion (see later).

Product Description

Cat No. of Pruducts

GMP-IVD-P048-Tg001-Ag01:Recombinant SARS-CoV2 Nucleocapsid Protein

Product Name

Recombinant SARS-CoV2 Nucleocapsid Protein

Target

Nucleocapsid protein

Alias of Target/Biomarker

#N/A

Expression platform

E.coli

Isotypes

Recombinant Antigen

Bioactivity validation

Nucleocapsid protein (Nucleocapsid) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Nucleocapsid level test of Infectious disease (COVID-19) and related syndrome evaluation

Tag

His

Products description

Recombinant SARS-CoV2 Nucleocapsid Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.

Reconized/Reactive Species

SARS-CoV2

Purity

Purity: ≥95% (SDS-PAGE)

Application

Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Genemeidi Omicron Variant Products
test
Previous slide
Next slide

Cat No. of Pruducts

GMP-IVD-P048-Tg001-Ab01,GMP-IVD-P048-Tg001-Ab02:Anti-SARS-CoV2 Nucleocapsid mouse monoclonal antibody (mAb)

Product Name

Anti-SARS-CoV2 Nucleocapsid mouse monoclonal antibody (mAb)

Target

Nucleocapsid protein (Nucleocapsid)

Alias of Target/Biomarker

#N/A

Expression platform

Hybridoma

Isotypes

Mouse IgG

Bioactivity validation

SARS-CoV2 Nucleocapsid protein (Nucleocapsid) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Nucleocapsid protein (Nucleocapsid) antibodies in Nucleocapsid level test of Infectious disease (COVID-19) and related syndrome evaluation.

Tag

mFc

Products description

Anti-SARS-CoV2 Nucleocapsid mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other Nucleocapsid protein (Nucleocapsid) antibodies.

Reconized/Reactive Species

SARS-CoV2

Purity

Purity: ≥95% (SDS-PAGE)

Application

ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1

Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.